Akers Biosciences, Inc. Form 8-K Filing (6571E)
October 19 2018 - 8:53AM
UK Regulatory
TIDMAKR
RNS Number : 6571E
Akers Biosciences, Inc.
19 October 2018
October 19, 2018
Akers Biosciences, Inc.
Form 8-K Filing
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a developer of rapid health information
technologies, announces that the Company has filed a Form 8-K with
the U.S. Securities and Exchange Commission concerning the
resignation of Richard C. Tarbox III, which was announced earlier
today. A copy of the Form 8-K is available to view on Akers Bio's
website at www.akersbio.com or on www.sec.gov and the text of the
Form 8-K appears below:
"Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On October 18, 2018, Richard C. Tarbox III submitted to the
board of directors (the "Board") of Akers Biosciences, Inc., (the
"Company") his resignation from his positions as interim
Non-Executive Chairman of the Board, as Secretary of the Company,
as a member of the Board and as a member of each of the committees
of the Board upon which he serves, effective immediately. Mr.
Tarbox's resignation was voluntary and as a result of his other
business commitments, and not a result of any disagreement with the
Company or its executive officers on any matter relating to the
Company's operations, policies or practices.
On October 19, 2018, as a result of Mr. Tarbox's resignation
from the Board and its committees the Board appointed Joshua
Silverman to its Audit Committee, Compensation Committee, and
Nominating and Corporate Governance Committee, having determined
that he satisfies all applicable requirements to serve on such
committees, including without limitation the applicable
requirements of NASDAQ.
Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
Following Mr. Tarbox's resignation as interim Non-Executive
Chairman of the Board to facilitate the election of its permanent
Chairman the Company has approved an amendment (the "Amendment") to
the Company's Amended and Restated Bylaws, as amended (the
"By-laws"), to provide that the Board of Directors may elect an
Executive Chairman of the Board, a Non-Executive Chairman of the
Board, and a Lead Independent Director of the Board, from among its
members.
The foregoing descriptions of the Amendment does not purport to
be complete and is subject to, and qualified in its entirety by,
the Amendment, a copy of which is attached hereto as Exhibit 3.1,
and incorporated herein by reference
[http://otp.investis.com/clients/us/akers_bioscience/SEC/sec-outline.aspx?FilingId=13014504&Cik=0001321834&PaperOnly=0&HasOriginal=1]."
Inquiries:
Akers Biosciences, Inc.
Howard R. Yeaton, Chief Executive Officer and interim Chief
Financial Officer
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Ed Frisby / Scott Mathieson (Corporate Finance)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7390 0234
Email: akers@vigocomms.com
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Note Regarding Forward-Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements reflect the Company's expectations about its future
operating results, performance and opportunities that involve
substantial risks and uncertainties. Such statements may include,
without limitation, statements with respect to the Company's plans,
compliance with the requirements of various regulatory agencies and
certain NASDAQ Stock Market listing rules, objectives, projections,
expectations and intentions and other statements identified by
words such as "projects," "may," "will," "could," "would," "should,
" "believes," "expects," "anticipates," "estimates," "intends,"
"plans," "potential" or similar expressions, as they relate to the
Company, its subsidiaries, or its management. These statements are
based upon the current beliefs and expectations of the Company's
management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the
Securities and Exchange Commission. Actual results, performance,
prospects, and opportunities to may differ materially from those
set forth in, or implied by, the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the Company's control). The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFFUFDUFASELS
(END) Dow Jones Newswires
October 19, 2018 09:53 ET (13:53 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2024 to May 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From May 2023 to May 2024